Holen Sie sich die Stockscreener-App
21.20
3.42%
-0.75
Schlusskurs vom Vortag:
$21.95
Offen:
$21.87
24-Stunden-Volumen:
183.61K
Relative Volume:
0.38
Marktkapitalisierung:
$1.04B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-85.21M
KGV:
-11.22
EPS:
-1.89
Netto-Cashflow:
$-68.53M
1W Leistung:
-6.44%
1M Leistung:
-1.40%
6M Leistung:
-3.02%
1J Leistung:
-15.27%
1-Tages-Spanne:
$21.04
$22.45
1-Wochen-Bereich:
$21.04
$23.41
52-Wochen-Spanne:
$13.30
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Firmenname
Enliven Therapeutics Inc
Sektor
Branche
Telefon
720-647-8519
Adresse
6200 LOOKOUT ROAD, BOULDER
Vergleichen Sie ELVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
21.20 | 1.29B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-16 | Eingeleitet | Goldman | Buy |
| 2024-12-13 | Eingeleitet | BTIG Research | Buy |
| 2024-09-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-09 | Eingeleitet | Mizuho | Buy |
| 2023-03-29 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Enliven Therapeutics Inc Aktie (ELVN) Neueste Nachrichten
What drives Enliven Therapeutics Inc. stock priceTremendous wealth creation - PrintWeekIndia
What risks could impact Enliven Therapeutics Inc. stock performanceMarket-beating returns - jammulinksnews.com
Will Enliven Therapeutics Inc. stock split in the near futureMoney Making Low Risk Plans - Newser
Polis encourages life-sciences companies to move to Colorado - BizWest
Enliven Therapeutics Inc. Stock Analysis and ForecastFree Wealth Planning Blueprint - Autocar Professional
BlackRock, Inc. Reduces Stake in Enliven Therapeutics Inc. - GuruFocus
What analysts say about Enliven Therapeutics Inc. stockOutstanding investment returns - Autocar Professional
Is Enliven Therapeutics Inc. a good long term investmentTriple-digit growth rates - Autocar Professional
Enliven Therapeutics CSO sells $278k in shares - Investing.com Australia
Enliven Therapeutics’ Promising CML Study Update: What Investors Need to Know - MSN
Samuel Kintz Sells 12,500 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - Defense World
Why Enliven Therapeutics Inc. stock attracts strong analyst attentionDaily Price Surge List - Newser
Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect? - MSN
Enliven Therapeutics’ Promising Phase 1a/1b Study on ELVN-002 in HER2+ Cancers - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Enliven Therapeutics (ELVN) - The Globe and Mail
Enliven Therapeutics’ Promising CML Treatment: A Study Update - TipRanks
What makes Enliven Therapeutics Inc. stock price move sharplyFree Investment Community - Newser
How Enliven Therapeutics Inc. stock performs during market volatilityInsider Strategy Insight - Newser
(ELVN) Proactive Strategies - news.stocktradersdaily.com
Enliven Therapeutics CFO Hohl sells $22,655 in shares - Investing.com Australia
Finanzdaten der Enliven Therapeutics Inc-Aktie (ELVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):